CA44974L3011 - Common Stock
IMV INC
NASDAQ:IMV (4/28/2023, 7:22:14 PM)
After market: 0.8 -0.02 (-2.74%)0.8225
-0.02 (-2.55%)
IMV, Inc. is a clinical-stage biopharmaceutical company, which engage in providing a novel class of cancer immunotherapies and vaccines against infectious diseases including COVID-19. The company is headquartered in Dartmouth, Nova Scotia and currently employs 63 full-time employees. The company went IPO on 2007-10-24. The firm is focused on developing a portfolio of therapies based on DPX, an immune-educating technology platform, that is designed to inform a specific anti-tumor immune response, offering benefit to patients with solid or hematological cancers. Its lead candidate, maveropepimut-S (MVP-S) is a DPX-based immunotherapy that targets survivin-expressing cells for elimination by educated, cytotoxic T cells. Its other candidates include DPX-RSV and DPX-COVID-19. DPX-RSV is a DPX-based vaccine candidate targeting the respiratory syncytial virus (RSV) strain A. The company is focused on developing DPX-COVID-19, a vaccine candidate against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by using its DPX platform. The firm is also developing maveropepimut-S for the treatment of breast and ovarian cancer, as well as for Diffuse large B-cell lymphoma (DLBCL) and other malignancies.
IMV INC
130 Eileen Stubbs Ave Suite 19
Dartmouth NOVA SCOTIA B3B 2C4
P: 19024921819.0
CEO: Frederic Ors
Employees: 63
Website: https://imv-inc.com/
/PRNewswire/ -- Horizon Technology Finance Corporation (NASDAQ: HRZN) ("HRZN", "Horizon" or the "Company"), a leading specialty finance company that provides...
H.C. Wainwright downgraded immuno-oncology company IMV Inc. to Neutral on Tuesday citing need for more clarity over its ongoing strategic review. Read more here.
Here you can normally see the latest stock twits on IMV, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: